Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
KRAS G12D
Advertisement
SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer at AACR 2026
New York, September 2, 2026 SELLAS Life Sciences Group, Inc. announced that three abstracts evaluating SLS009 (tambiciclib), a potent...
IDEAYA and Genentech Advance KRAS G12D Cancer Trial
South San Francisco, California, August 19, 2026 IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member...
Verastem Oncology Doses First Patient in TARGET-D 203 Trial
BOSTON, July 28, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 203 Phase...
Verastem Oncology Doses First Patient in Phase 2 VS-7375 NSCLC Trial
BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...
Advertisements
Incyte Showcases Oncology Pipeline at ESMO Congress 2026
WILMINGTON, Del., July 17, 2026 Incyte has announced that it will present six oncology studies, including four rapid oral...
Revolution Medicines Presents RAS(ON) Data at ESMO 2026
REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...
Verastem Oncology Doses First Patient in TARGET-D 201 Trial
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
Advertisement
